Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion

Philip Scheltens, Nick Fox, Frederik Barkhof, Charles DeCarli

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

Neuroimaging is increasingly used to aid diagnosis in dementia. The traditional view that imaging is important solely as means of excluding treatable causes of dementia is maintained by many guidelines. These conditions however, account for a tiny proportion (<1%) of all causes of dementia. Over the past few years it has been recognised that a more accurate diagnosis and prognosis is important for patients and their families. The different pathological processes that produce cerebral dysfunction at a cellular level also produce macroscopic effects that can be detected in vivo with imaging. Clinically useful measures that distinguish between neurodegenerative disorders at an early stage are still awaited. The most likely future use of structural imaging will be the identification of patients at risk for Alzheimer's disease or with preclinical Alzheimer's disease. For magnetic resonance imaging (MRI) this will mean focusing on those areas that are affected earliest in the disease; ie, entorhinal cortex and hippocampus, using high resolution structural MRI or sophisticated brain mapping techniques. Imaging research is also likely to focus on measuring progression and detecting therapeutic effect. As such, MRI is already become an indispensable tool in clinical trials in dementia.

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalLancet Neurology
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2002

Fingerprint

Dementia
Magnetic Resonance Imaging
Alzheimer Disease
Brain Mapping
Entorhinal Cortex
Therapeutic Uses
Pathologic Processes
Neuroimaging
Neurodegenerative Diseases
Hippocampus
Clinical Trials
Guidelines
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Structural magnetic resonance imaging in the practical assessment of dementia : Beyond exclusion. / Scheltens, Philip; Fox, Nick; Barkhof, Frederik; DeCarli, Charles.

In: Lancet Neurology, Vol. 1, No. 1, 01.01.2002, p. 13-21.

Research output: Contribution to journalArticle

Scheltens, Philip ; Fox, Nick ; Barkhof, Frederik ; DeCarli, Charles. / Structural magnetic resonance imaging in the practical assessment of dementia : Beyond exclusion. In: Lancet Neurology. 2002 ; Vol. 1, No. 1. pp. 13-21.
@article{f8130f87c6f0498389142b6749c5a7f0,
title = "Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion",
abstract = "Neuroimaging is increasingly used to aid diagnosis in dementia. The traditional view that imaging is important solely as means of excluding treatable causes of dementia is maintained by many guidelines. These conditions however, account for a tiny proportion (<1{\%}) of all causes of dementia. Over the past few years it has been recognised that a more accurate diagnosis and prognosis is important for patients and their families. The different pathological processes that produce cerebral dysfunction at a cellular level also produce macroscopic effects that can be detected in vivo with imaging. Clinically useful measures that distinguish between neurodegenerative disorders at an early stage are still awaited. The most likely future use of structural imaging will be the identification of patients at risk for Alzheimer's disease or with preclinical Alzheimer's disease. For magnetic resonance imaging (MRI) this will mean focusing on those areas that are affected earliest in the disease; ie, entorhinal cortex and hippocampus, using high resolution structural MRI or sophisticated brain mapping techniques. Imaging research is also likely to focus on measuring progression and detecting therapeutic effect. As such, MRI is already become an indispensable tool in clinical trials in dementia.",
author = "Philip Scheltens and Nick Fox and Frederik Barkhof and Charles DeCarli",
year = "2002",
month = "1",
day = "1",
doi = "10.1016/S1474-4422(02)00002-9",
language = "English (US)",
volume = "1",
pages = "13--21",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Structural magnetic resonance imaging in the practical assessment of dementia

T2 - Beyond exclusion

AU - Scheltens, Philip

AU - Fox, Nick

AU - Barkhof, Frederik

AU - DeCarli, Charles

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Neuroimaging is increasingly used to aid diagnosis in dementia. The traditional view that imaging is important solely as means of excluding treatable causes of dementia is maintained by many guidelines. These conditions however, account for a tiny proportion (<1%) of all causes of dementia. Over the past few years it has been recognised that a more accurate diagnosis and prognosis is important for patients and their families. The different pathological processes that produce cerebral dysfunction at a cellular level also produce macroscopic effects that can be detected in vivo with imaging. Clinically useful measures that distinguish between neurodegenerative disorders at an early stage are still awaited. The most likely future use of structural imaging will be the identification of patients at risk for Alzheimer's disease or with preclinical Alzheimer's disease. For magnetic resonance imaging (MRI) this will mean focusing on those areas that are affected earliest in the disease; ie, entorhinal cortex and hippocampus, using high resolution structural MRI or sophisticated brain mapping techniques. Imaging research is also likely to focus on measuring progression and detecting therapeutic effect. As such, MRI is already become an indispensable tool in clinical trials in dementia.

AB - Neuroimaging is increasingly used to aid diagnosis in dementia. The traditional view that imaging is important solely as means of excluding treatable causes of dementia is maintained by many guidelines. These conditions however, account for a tiny proportion (<1%) of all causes of dementia. Over the past few years it has been recognised that a more accurate diagnosis and prognosis is important for patients and their families. The different pathological processes that produce cerebral dysfunction at a cellular level also produce macroscopic effects that can be detected in vivo with imaging. Clinically useful measures that distinguish between neurodegenerative disorders at an early stage are still awaited. The most likely future use of structural imaging will be the identification of patients at risk for Alzheimer's disease or with preclinical Alzheimer's disease. For magnetic resonance imaging (MRI) this will mean focusing on those areas that are affected earliest in the disease; ie, entorhinal cortex and hippocampus, using high resolution structural MRI or sophisticated brain mapping techniques. Imaging research is also likely to focus on measuring progression and detecting therapeutic effect. As such, MRI is already become an indispensable tool in clinical trials in dementia.

UR - http://www.scopus.com/inward/record.url?scp=0001792170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001792170&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(02)00002-9

DO - 10.1016/S1474-4422(02)00002-9

M3 - Article

C2 - 12849541

AN - SCOPUS:0001792170

VL - 1

SP - 13

EP - 21

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -